Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

Advanced Technologies and Strategic Partnerships Accelerate Sustainable Agriculture Efforts Zero-Waste Inspired® Mission Continues to Drive ...

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...